APA

Park B., Kim W. S., Lee J., Park K. W., Kang J., Lee S., Park J. O., Kim K., Jung C. W., Park Y. S., Im Y., Kang W. K., Ko Y., Lee M. H. & Park K. (20060327). IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. : Leukemia & lymphoma.

Chicago

Park B-B, Kim W S, Lee J, Park K W, Kang J-H, Lee S-H, Park J O, Kim K, Jung C W, Park Y S, Im Y-H, Kang W K, Ko Y-H, Lee M H and Park K. 20060327. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. : Leukemia & lymphoma.

Harvard

Park B., Kim W. S., Lee J., Park K. W., Kang J., Lee S., Park J. O., Kim K., Jung C. W., Park Y. S., Im Y., Kang W. K., Ko Y., Lee M. H. and Park K. (20060327). IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. : Leukemia & lymphoma.

MLA

Park B-B, Kim W S, Lee J, Park K W, Kang J-H, Lee S-H, Park J O, Kim K, Jung C W, Park Y S, Im Y-H, Kang W K, Ko Y-H, Lee M H and Park K. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. : Leukemia & lymphoma. 20060327.